EA028756B1 - Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы - Google Patents

Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы Download PDF

Info

Publication number
EA028756B1
EA028756B1 EA201591908A EA201591908A EA028756B1 EA 028756 B1 EA028756 B1 EA 028756B1 EA 201591908 A EA201591908 A EA 201591908A EA 201591908 A EA201591908 A EA 201591908A EA 028756 B1 EA028756 B1 EA 028756B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
phenoxyphenyl
alkenyl
compound
mmol
Prior art date
Application number
EA201591908A
Other languages
English (en)
Russian (ru)
Other versions
EA201591908A1 (ru
Inventor
Юньхан Го
Чживэй Ван
Original Assignee
Бэйджин, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бэйджин, Лтд. filed Critical Бэйджин, Лтд.
Publication of EA201591908A1 publication Critical patent/EA201591908A1/ru
Publication of EA028756B1 publication Critical patent/EA028756B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EA201591908A 2013-04-25 2014-04-22 Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы EA028756B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/074728 2013-04-25
PCT/CN2014/075943 WO2014173289A1 (en) 2013-04-25 2014-04-22 Fused heterocyclic compounds as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201591908A1 EA201591908A1 (ru) 2016-05-31
EA028756B1 true EA028756B1 (ru) 2017-12-29

Family

ID=51791057

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591908A EA028756B1 (ru) 2013-04-25 2014-04-22 Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы

Country Status (29)

Country Link
US (8) US9447106B2 (enExample)
EP (1) EP2989106B1 (enExample)
JP (1) JP6204568B2 (enExample)
KR (1) KR101793807B1 (enExample)
CN (1) CN104884458B (enExample)
AU (1) AU2014256633B2 (enExample)
BR (1) BR112015025260B1 (enExample)
CA (1) CA2902686C (enExample)
CY (2) CY1118834T1 (enExample)
DK (1) DK2989106T3 (enExample)
EA (1) EA028756B1 (enExample)
ES (1) ES2619125T3 (enExample)
FR (1) FR22C1010I2 (enExample)
HR (1) HRP20170217T1 (enExample)
HU (2) HUE031980T2 (enExample)
LT (2) LT2989106T (enExample)
LU (1) LUC00250I2 (enExample)
MX (1) MX367918B (enExample)
NL (1) NL301161I2 (enExample)
NO (1) NO2022005I1 (enExample)
NZ (1) NZ711540A (enExample)
PL (1) PL2989106T3 (enExample)
PT (1) PT2989106T (enExample)
RS (1) RS55770B1 (enExample)
SG (1) SG11201506764WA (enExample)
SI (1) SI2989106T1 (enExample)
SM (1) SMT201700160T1 (enExample)
WO (1) WO2014173289A1 (enExample)
ZA (1) ZA201508504B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902686C (en) * 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
CN108715615B (zh) 2013-09-13 2020-11-27 百济神州(广州)生物科技有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN104341388B (zh) 2013-10-16 2017-03-22 北京诺诚健华医药科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
PL3179992T3 (pl) 2014-08-11 2022-08-16 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1
TW201618774A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
CA2966259A1 (en) * 2014-11-03 2016-05-12 Bayer Pharma Aktiengesellschaft Piperidinylpyrazolopyrimidinones and their use
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
CN106588913B (zh) * 2015-10-16 2018-11-02 陈剑 具有咪唑并吡啶类衍生物，其制备及其在医药上的应用
KR102684436B1 (ko) 2015-10-16 2024-07-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Ep4 길항제
ES2839408T3 (es) 2016-01-13 2021-07-05 Acerta Pharma Bv Combinaciones terapéuticas de un antifolato y un inhibidor de BTK
CN105732638B (zh) * 2016-01-22 2018-01-30 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
DK3500299T3 (da) * 2016-08-19 2024-01-29 Beigene Switzerland Gmbh Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
MX390121B (es) 2016-09-19 2025-03-20 Mei Pharma Inc Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN110799543A (zh) 2017-06-26 2020-02-14 百济神州有限公司 肝细胞癌的免疫治疗
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
EP3689877A4 (en) * 2017-11-03 2020-08-19 South China Agricultural University MERGED TRICYCLIC COMPOUND CONTAINING NITROGEN AND ITS USE AS AN AGROFORESTRY INSECTICIDE
CN111801334B (zh) * 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
EP3883649A1 (en) 2018-05-17 2021-09-29 Avidin KFT Imidazo-pyrazole carboxamide derivatives as anticancer agents and the synthesis thereof
CN108467397A (zh) * 2018-05-25 2018-08-31 陈海鹏 一种含有氰基的三环类化合物及其在抗肿瘤药物中的用途
CN108484615A (zh) * 2018-05-25 2018-09-04 陈海鹏 一种化合物、合成方法及其在制备抗肿瘤药物中的用途
CN108558886A (zh) * 2018-05-25 2018-09-21 陈海鹏 一种含有氰基的三环类化合物及其在制备抗肿瘤药物中的用途
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
US20220362357A1 (en) 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
CN111909152B (zh) * 2019-05-08 2023-12-15 百济神州(苏州)生物科技有限公司 Btk抑制剂及其中间体的制备方法
EP3966204B1 (en) * 2019-05-10 2024-11-27 Henan Zhiwei Biomedicine Co., Ltd. Substituted 1-amino-1h-imidazole-5-carboxamide as bruton's tyrosine kinase inhibitors
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
EP3981400A4 (en) * 2019-06-10 2023-07-12 BeiGene Switzerland GmbH Oral capsule and preparation method therefor
EP3981399A4 (en) * 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
CN114174299B (zh) * 2019-07-26 2024-10-25 百济神州有限公司 通过btk抑制剂与e3连接酶配体缀合对布鲁顿氏酪氨酸激酶(btk)的降解以及使用方法
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
EP4051680B1 (en) 2019-10-30 2025-09-03 Biogen MA Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
WO2021110142A1 (en) * 2019-12-04 2021-06-10 Henan Normal University Substituted imidazolecarboxamide as bruton's tyrosine kinase inhibitors
CN110845504A (zh) * 2019-12-19 2020-02-28 武汉九州钰民医药科技有限公司 合成赞布替尼的新方法
CN115175678B (zh) * 2020-02-27 2024-12-27 百济神州瑞士有限责任公司 使用btk抑制剂及其组合治疗dlbcl的方法
TW202200574A (zh) 2020-04-15 2022-01-01 英屬開曼群島商百濟神州有限公司 Bcl-2抑制劑
WO2021259732A1 (en) 2020-06-24 2021-12-30 Sandoz Ag Multi-component compounds comprising zanubrutinib and a benzoic acid derivative
CN116018138B (zh) * 2020-07-13 2025-08-15 河南知微生物医药有限公司 作为布鲁诺酪氨酸激酶抑制剂的取代的1H-咪唑并[1,2-b]吡唑-3-甲酰胺
CN113943293A (zh) * 2020-07-16 2022-01-18 百济神州(北京)生物科技有限公司 用于制备作为protac btk降解剂的双官能化合物的方法
KR20230051227A (ko) 2020-08-14 2023-04-17 노파르티스 아게 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도
US20250073238A1 (en) * 2020-11-20 2025-03-06 Beigene Switzerland Gmbh Methods of treating systemic lupus erythematosus using btk inhibitors
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
US20240124461A1 (en) 2020-12-11 2024-04-18 Teva Pharmaceuticals International Gmbh Processes for the preparation of zanubrutinib and intermediates thereof
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN116981675A (zh) * 2020-12-31 2023-10-31 百济神州有限公司 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
EP4284434A4 (en) * 2021-01-30 2024-12-25 BeiGene Switzerland GmbH METHODS FOR TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
TW202317558A (zh) * 2021-06-21 2023-05-01 英屬開曼群島商百濟神州有限公司 （ｒ）－戊二醯亞胺ｃｒｂｎ配位體及使用方法
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
IT202100025997A1 (it) * 2021-10-11 2023-04-11 Olon Spa Processo per la preparazione di zanubrutinib
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004497A1 (en) * 2001-07-05 2003-01-16 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compound
WO2004017908A2 (en) * 2002-08-26 2004-03-04 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体
WO2012143522A1 (en) * 2011-04-20 2012-10-26 Glaxo Group Limited Tetrahydropyrazolo [1,5 -a] pyrimidine as anti -tuberculosis compounds

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792533A (fr) 1971-12-09 1973-06-08 Int Chem & Nuclear Corp Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
JP2778921B2 (ja) 1994-11-18 1998-07-23 三共株式会社 イミダゾピラゾール誘導体
EP1206474B1 (en) 1999-08-27 2004-05-26 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
DE60207390T2 (de) 2001-03-09 2006-07-20 Pfizer Products Inc., Groton Entzündungshemmende benzimidazolverbindungen
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
BRPI0413005A (pt) 2003-07-29 2006-09-26 Irm Llc compostos e composições como inibidores da proteìna cinase
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
BRPI0517619A (pt) 2004-11-10 2008-10-14 Cgi Pharmaceuticals Inc entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos
JP2008524233A (ja) 2004-12-16 2008-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 炎症性疾患、増殖性疾患および免疫介在性疾患の治療のためのｔｅｃファミリータンパク質キナーゼのインヒビターとして有用なピリド−２−オン
EP1863766B1 (en) 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
US7786130B2 (en) 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
EP1919891B1 (en) 2005-08-29 2012-03-07 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
CA2620740A1 (en) 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
BRPI0621027A2 (pt) 2006-01-13 2011-11-29 Pharmacyclics Inc composto, composição farmacêutica
WO2007136790A2 (en) 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PE20081370A1 (es) 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
ES2673973T3 (es) 2006-09-22 2018-06-26 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
MX2009003649A (es) 2006-10-06 2009-04-22 Irm Llc Inhibidores de cinasa de proteina y metodos para utilizarlos.
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
AU2008314632B2 (en) 2007-10-19 2015-05-28 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
SG185330A1 (en) 2007-10-23 2012-11-29 Hoffmann La Roche Novel kinase inhibitors
ES2462642T3 (es) 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
JP5259739B2 (ja) 2008-02-05 2013-08-07 エフ．ホフマン−ラ ロシュ アーゲー 新規ピリジノン及びピリダジノン
WO2009137596A1 (en) 2008-05-06 2009-11-12 Cgi Pharmaceuticals, Inc. Substituted amides, method of making, and use as btk inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
BRPI0913879A2 (pt) 2008-07-02 2019-09-24 Hoffmann La Roche fenilpirazinonas como inibidores de quinase
WO2010006947A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
WO2010006970A1 (en) 2008-07-18 2010-01-21 F. Hoffmann-La Roche Ag Novel phenylimidazopyrazines
JP2011529073A (ja) 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
RU2014150660A (ru) 2008-09-05 2015-07-20 Селджен Авиломикс Рисерч, Инк. Алгоритм разработки необратимо действующих ингибиторов
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
PE20110819A1 (es) 2008-12-19 2011-11-02 Bristol Myers Squibb Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa
US9266890B2 (en) 2009-01-06 2016-02-23 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2748414A1 (en) 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
NZ598985A (en) 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011140488A1 (en) 2010-05-07 2011-11-10 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
EP3590938B1 (en) 2010-05-31 2023-05-24 ONO Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
USRE46511E1 (en) 2010-06-23 2017-08-15 Hanmi Science Co., Ltd. Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2611790B1 (en) 2010-09-01 2015-11-04 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
CN103201277B (zh) 2010-09-01 2015-11-25 吉利德康涅狄格有限公司 哒嗪酮、其制备方法及使用方法
US8703767B2 (en) 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
CA2760174A1 (en) 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
WO2012158795A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
MX345170B (es) 2011-05-17 2017-01-19 Hoffmann La Roche Inhibidores de la tirosina-cinasa de bruton.
HUE033019T2 (en) 2011-05-17 2017-11-28 Principia Biopharma Inc Tyrosine kinase inhibitors
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
PT2718270T (pt) 2011-06-10 2022-07-29 Merck Patent Gmbh Composições e métodos para a produção de compostos de pirimidina e piridina com atividade inibidora de btk
WO2013008095A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
CA2902686C (en) * 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
CN108715615B (zh) 2013-09-13 2020-11-27 百济神州(广州)生物科技有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
MA41197B1 (fr) 2014-12-18 2021-01-29 Principia Biopharma Inc Traitement de le pemphigus
PL3236943T3 (pl) 2014-12-24 2023-05-29 Principia Biopharma Inc. Kompozycje do krętniczo-czczego dostarczania leków
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
US20190054090A1 (en) 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
DK3500299T3 (da) 2016-08-19 2024-01-29 Beigene Switzerland Gmbh Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
AU2018253951A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004497A1 (en) * 2001-07-05 2003-01-16 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compound
WO2004017908A2 (en) * 2002-08-26 2004-03-04 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体
WO2012143522A1 (en) * 2011-04-20 2012-10-26 Glaxo Group Limited Tetrahydropyrazolo [1,5 -a] pyrimidine as anti -tuberculosis compounds

Also Published As

Publication number Publication date
KR101793807B1 (ko) 2017-11-03
US20200148690A1 (en) 2020-05-14
SG11201506764WA (en) 2015-09-29
US11142528B2 (en) 2021-10-12
MX2015013481A (es) 2016-08-03
HK1222174A1 (en) 2017-06-23
US20240254128A1 (en) 2024-08-01
SMT201700160T1 (it) 2017-05-08
PT2989106T (pt) 2017-03-15
MX367918B (es) 2019-09-11
US20250340560A1 (en) 2025-11-06
US20180251466A1 (en) 2018-09-06
ZA201508504B (en) 2017-02-22
JP2016521273A (ja) 2016-07-21
AU2014256633A1 (en) 2015-09-17
ES2619125T3 (es) 2017-06-23
US9447106B2 (en) 2016-09-20
BR112015025260A2 (pt) 2017-07-18
LTPA2022504I1 (enExample) 2022-04-11
SI2989106T1 (sl) 2017-07-31
CY2022004I1 (el) 2022-07-22
CA2902686A1 (en) 2014-10-30
NZ711540A (en) 2018-08-31
US10570139B2 (en) 2020-02-25
LT2989106T (lt) 2017-04-10
US20170073349A1 (en) 2017-03-16
FR22C1010I1 (fr) 2022-05-06
US20160083392A1 (en) 2016-03-24
JP6204568B2 (ja) 2017-09-27
HRP20170217T1 (hr) 2017-04-21
US10005782B2 (en) 2018-06-26
LTC2989106I2 (enExample) 2024-11-25
CN104884458A (zh) 2015-09-02
HUE031980T2 (en) 2017-08-28
CY2022004I2 (el) 2022-07-22
NL301161I2 (nl) 2022-04-06
CY1118834T1 (el) 2018-01-10
DK2989106T3 (en) 2017-03-20
PL2989106T3 (pl) 2017-08-31
AU2014256633B2 (en) 2017-02-02
HUS2200010I1 (hu) 2022-04-28
CA2902686C (en) 2017-01-24
US20150259354A1 (en) 2015-09-17
EA201591908A1 (ru) 2016-05-31
RS55770B1 (sr) 2017-07-31
EP2989106A1 (en) 2016-03-02
FR22C1010I2 (fr) 2023-02-03
EP2989106A4 (en) 2016-03-02
CN104884458B (zh) 2017-04-12
NO2022005I1 (no) 2022-02-03
EP2989106B1 (en) 2016-12-14
US20230013862A1 (en) 2023-01-19
US9556188B2 (en) 2017-01-31
KR20160002812A (ko) 2016-01-08
BR112015025260B1 (pt) 2021-11-03
WO2014173289A1 (en) 2014-10-30
LUC00250I2 (enExample) 2025-03-04

Similar Documents

Publication Publication Date Title
US11142528B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
CA2975033C (en) Cdk2/4/6 inhibitors
JP7721501B2 (ja) Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
DK2797921T3 (en) FUSED TETRA- OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARB INHIBITORS
ES2924371T3 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
US20150005277A1 (en) Protein Kinase Inhibitors and Uses Thereof
CN112584898B (zh) P2x3受体拮抗剂
TW202523668A (zh) 四環衍生物、其組成物及方法
TWI602818B (zh) 稠合雜環化合物作爲蛋白激酶抑制劑
HK1222174B (en) Fused heterocyclic compounds as protein kinase inhibitors
HK1244787B (zh) 作为吲哚胺、色氨酸二加氧酶抑制剂的5或8-取代的咪唑并[1，5-a]吡啶

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
ND4A Extension of term of a eurasian patent